Search clinical trials for: Gemcitabine / Cisplatin / Sorafenib

Total 6390 results

Lahey Clinic

Withdrawn

Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
Memorial Sloan Kettering Cancer Center
Bayer

Terminated

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer | URINARY BLADDER

United States
Gyeongsang National University Hospital
Samsung Medical Center; Dong-A University; Chung-Ang University

Terminated

Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

Korea, Republic of
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
Gruppo Italiano per lo studio dei Carcinomi dell...
Mario Negri Institute for Pharmacological Research

Unknown

Metastatic Advanced Pancreas Sorafenib (MAPS)

Locally Advanced Pancreatic Cancer

Italy
Kansai Hepatobiliary Oncology Group

Completed

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Biliary Tract Cancer

Japan
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

Bladder Cancer

Italy
Asan Medical Center
Bayer

Completed

Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE

Effects of Chemotherapy | Malignant Neoplasm of Stomach

Korea, Republic of
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaborators

Active, not recruiting

GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
Indiana University School of Medicine
Amgen

Completed

Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer

Pancreatic Cancer | Adenocarcinoma of the Pancreas

United States
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

HER2 Gene Mutation

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Institut du Cancer de Montpellier - Val d'Aurelle

Active, not recruiting

A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer (GETUGV04)

Infiltrating Bladder Urothelial Carcinoma

France
Asan Medical Center

Completed

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

Advanced Gastric Cancer

Korea, Republic of
Bayer

Completed

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) (NEXUS)

Carcinoma, Non-Small-Cell Lung

Belgium, Spain, France, Switzerland, Greece, Italy, Hungary, Canada, Netherlands, United Kingdom, Austria, China, Israel, Mexico, Germany, Brazil, Finland, Cyprus
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Barmherzige Brüder Vienna

Completed

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

Bladder Cancer

Austria
Sun Yat-sen University

Unknown

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

China
Kansai Hepatobiliary Oncology Group

Completed

Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer

Biliary Tract Cancer

Japan
Hua Li

Recruiting

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

China
Akeso

Recruiting

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China, United States, Australia, Brazil, Canada
Hannover Medical School

Completed

PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) (PiCCA)

Cholangiocarcinomas

Germany
Tata Memorial Centre

Recruiting

Radiation Therapy in Unresectable Gall Bladder Cancer (RUGB)

Gall Bladder Cancer

India
University College, London
Eli Lilly and Company

Completed

Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors (ABC-02)

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United Kingdom
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor...

Recruiting

Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Kindai University

Completed

Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy (SILIUS)

Hepatocellular Carcinoma

Japan
Kansai Hepatobiliary Oncology Group

Completed

A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy

Biliary Tract Cancer

Japan
Spanish Lung Cancer Group

Terminated

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma (BREC)

Non Small Cell Lung Cancer | BRCA1 Mutation

Spain
First People's Hospital of Foshan

Unknown

Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The European Uro-Oncology Group
Centre for Human Drug Research, Netherlands

Recruiting

Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (URANUS)

Upper Tract Urothelial Carcinoma

Norway, Spain, Netherlands
Sun Yat-sen University
Peking University; Zhejiang Cancer Hospital; Fudan University; West China Hospital and other collaborators

Unknown

Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Kuwait Cancer Control Center

Recruiting

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Kuwait
Sirtex Medical

Completed

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Intrahepatic Cholangiocarcinoma

France, United Kingdom, Belgium, Australia, Spain, United States, Italy, Netherlands
BeiGene

Active, not recruiting

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent or Metastatic Nasopharyngeal Cancer

China, Taiwan, Thailand
Chaosu Hu
Zhejiang Cancer Hospital; Fujian Cancer Hospital; Affiliated Hospital of Jiangnan... and other collaborators

Recruiting

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
Sierra Oncology LLC - a GSK company

Completed

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Advanced Solid Tumors

Spain, United Kingdom
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Active, not recruiting

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
Shantou University Medical College

Unknown

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

Pleural Effusion, Malignant

China
Kansai Hepatobiliary Oncology Group

Unknown

A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

Biliary Tract Cancer

Japan
Kansai Hepatobiliary Oncology Group

Completed

Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

Japan
The First Affiliated Hospital of Soochow University

Recruiting

Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

Acute Myeloid Leukemia, Adult

China
Yung NA
Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern Hospital

Recruiting

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial

Muscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial Carcinoma

Hong Kong
PharmaMar

Completed

Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors | Lymphomas

France, United States
Yabao Pharmaceutical Group

Completed

Bioequivalence Study of Sorafenib Tablet and Nexavar

Fasting

Canada
Bayer

Terminated

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Carcinoma, Renal Cell

United States
Institut Paoli-Calmettes

Unknown

Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

France
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Bladder Cancer

United States, Canada

3

Subscribe